Posts tagged “GSK”

11:48 a.m. yesterday

Premium Lock FDA OKs Glaxo's inhaler which is first one to combine 3 medicines

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.

Glaxo Inhaler Glaxo Inhaler

Updated August 4

Premium Lock United Therapeutics jumps on takeover talk; GSK a potential bidder

United Therapeutics United Therapeutics, which has a major operation in RTP, could be a takeover for three pharmaceutical giants, including GlaxoSmithKline. United Therapeutics stock surged on Wall Street early Friday.

August 4

Premium Lock G1 Therapeutics recruits former senior QuintilesIMS, GSK execs

G1 Therapeutics, which went public in May for more than $100 million and recently added retired GSK CEO Andrew Witty to its board, keeps recruiting management talent.

G1 targets cancer G1 targets cancer

July 26

Premium Lock GSK's new CEO unveils strategic shakeup strategy (+ video)

Drug giant GlaxoSmithKline's new CEO Emma Walmsley utilized the timing of GSK's latest earnings report to unveil the new strategic direction in which she intends to take the company. A key point of emphasis is HIV, which could mean good news for the Triangle.

July 25

Premium Lock GSK's new CEO continues reshaping drug giant with new female CTO

Emma Walmsley, the first female CEO of GlaxoSmithKline, is adding another female voice to the drug giant's management team.

Karenann Terrell Karenann Terrell

July 13

Premium Lock G1 Therapeutics names former GSK top exec Andrew Witty to board

Andrew Witty, formerly CEO of drug giant GlaxoSmithKline, is now a member of the board of directors at RTP-based G1 Therapeutics.

Andrew Witty          Andrew Witty

July 3

Premium Lock GSK turns to AI to speed up drug development, invests $43M in startup

GSK in Zebulon     GlaxoSmithKline sees the potential of using artificial intelligence to boost drug development. And its latest investment in a startup reflects that commitment. Plus: A profile of the GSK-backed startup.

June 20

Premium Lock In a short filing, GSK confirms deal for new pharma CEO

GSK's HQ in London               GlaxoSmithKline will have a new head of pharmaceutical operations as of Sept. 4 after settling a dispute with rival AstraZeneca over the poaching of one of its top executives.

May 30

Premium Lock New $80M look for GSK's Triangle campus coming under ownership change

Glaxo Smith Kline's sprawling campus in Research Triangle Park is heading toward a major remodeling under new owner Parmer Innovation, which is promising "one of the most influential amenity parks in the Southeast."

GSK leases Charles Sanders center GSK leases Charles Sanders center

Updated April 26

Premium Lock GSK revenues surge yet generic drugs pose big threat

GlaxoSmithKline says new products helped first-quarter sales rise 17 percent from the year before but warned that competition from generic drugs may weigh on earnings later this year.

Updated April 25

Premium Lock Dish unveils $999 system to make live online video easier (+ video)

Dish, a company known largely for its old-school satellite TV, is now trying to make it easier for people to stream quality video live over YouTube and Facebook.

Updated March 15

Premium Lock GSK will pay first female CEO 25% less than Andrew Witty

GlaxoSmithKline says in its annual report that it will pay incoming CEO Emma Walmsley - the first woman to lead a top drug maker - some 25 percent less than the man she is replacing.

March 15

Premium Lock Couple sue GlaxoSmithKline for work that led to prison in China

Peter Humphrey and Yu Yingzeng, back in Britain with health problems and in financial ruin, are now suing GSK for allegedly misleading them on what the job was about and exposing them to legal risks in China they could not have foreseen. GSK says there's no merit to the claim.

Peter Humphrey Peter Humphrey

Updated January 19

Premium Lock GSK pharma chief to quit after losing out on CEO job

GSK's HQ in London               GlaxoSmithKline's head of pharmaceuticals is leaving the drug giant after losing out in the race to replace retiring CEO Andrew Witty. GSK is hiring an AstraZeneca exec to replace him.

December 20, 2016

Premium Lock GSK launches trial for long-acting injection to prevent HIV

HIV AIDS research   GlaxoSmithKline's ViiV Healthcare is launching a phase 3 clinical trial of a long-lasting injection that could prevent the HIV virus.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith